Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €63.56 EUR
Change Today -0.84 / -1.31%
Volume 86.0K
GXI On Other Exchanges
As of 1:31 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

gerresheimer ag (GXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - €68.64
52 Week Low
10/16/14 - €41.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GERRESHEIMER AG (GXI)

Related News

No related news articles were found.

gerresheimer ag (GXI) Related Businessweek News

No Related Businessweek News Found

gerresheimer ag (GXI) Details

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates in three divisions: Plastics and Devices, Primary Packaging Glass, and Life Science Research. The Plastics and Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. This division also provides containers for the delivery of tablets and powder, liquid dosage, ophthalmic and rhinological applications, and parenteral packaging applications. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials and syringe barrels, cartridges, syrup and dropper bottles, tablet jars, wide-neck jars and injections, and infusion and transfusion bottles; and flacons and pots for fragrances, deodorants, care and decorative cosmetics, etc., as well as specialty containers for spirits and food. The Life Science Research division produces reusable laboratory glassware for the research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders; and disposable laboratory products, including culture tubes, pipettes, chromatography vials, and other specialty laboratory glassware. Gerresheimer AG was founded in 1864 and is headquartered in Düsseldorf, Germany.

11,036 Employees
Last Reported Date: 07/8/15
Founded in 1864

gerresheimer ag (GXI) Top Compensated Officers

Chairman of the Management Board and Chief Ex...
Total Annual Compensation: €1.1M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €855.0K
Member of the Management Board
Total Annual Compensation: €805.0K
Compensation as of Fiscal Year 2014.

gerresheimer ag (GXI) Key Developments

Gerresheimer AG, Centor, Inc. - M&A Call

To discuss on the acquisition of Centor

Gerresheimer AG Revised Earnings Guidance for the Fiscal Year 2016 to 2018

Gerresheimer AG revised earnings guidance for the fiscal year 2016 to 2018. Assuming a completion of the Centor acquisition during the fourth quarter of the financial year 2015, Gerresheimer's first indication for the financial years 2016 to 2018 is as follows: Annual organic revenue growth is expected to average 4% to 5% against previous mid-term outlook, dating July 9, 2015: 4% to 6% - on a higher revenue base increased by Centor revenues (full year 2014 USD 167 million (pro forma)). Organic growth means a growth at constant FX rates, excluding acquisitions, divestments and optimizations of the business portfolio. The adjusted EBITDA margin will amount to approximately 22% by 2018 at constant exchange rates against previous mid-term outlook, dating July 9, 2015: approximately 20%. Capital expenditure will be in the range of 8.0% to 9.0% of revenues at constant exchange rates against previous mid-term outlook, dating July 9, 2015 of 8.0% to 9.5% of revenues.

Gerresheimer AG Reports Earnings Results for the Second Quarter of 2015; Provides Earnings Guidance for the Year 2015

Gerresheimer AG reported earnings results for the second quarter of 2015. For the quarter, the company generated adjusted EBITDA of EUR 72.1 million, an improvement of 10.6% on the prior-year quarter. Adjusted EBITDA came to EUR 70.3 million. Net income was EUR 22.4 million, 7.4% higher than in the prior-year quarter. Earnings per share stood at EUR 0.65, compared with EUR 0.61 a year earlier. Adjusted earnings per share came to EUR 0.84, versus EUR 0.73 in the comparative prior-year quarter. Capital expenditure was EUR 19.9 million, as against EUR 25.1 million in the prior-year quarter. For the year 2015, the company anticipates organic revenue growth of between 1% and 3%. This corresponds to a revenue corridor of some EUR 1,300 million to EUR 1,330 million. Adjusted EBITDA, Gerresheimer expects an increase in a target corridor of EUR 255 million to EUR 265 million. Capital expenditure is forecast to represent around 9% to 10% of revenues at constant exchange rates.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GXI:GR €63.56 EUR -0.84

GXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Carclo PLC 149.25 GBp -1.25
Consort Medical PLC 973.50 GBp -3.50
Vitro SAB de CV $61.12 MXN -0.34
West Pharmaceutical Services Inc $55.04 USD -0.30
Zignago Vetro SpA €5.28 EUR -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation GXI Industry Range
Price/Earnings 29.8x
Price/Sales 1.6x
Price/Book 3.8x
Price/Cash Flow 29.8x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERRESHEIMER AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at